Matches in SemOpenAlex for { <https://semopenalex.org/work/W192248603> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W192248603 endingPage "45" @default.
- W192248603 startingPage "139" @default.
- W192248603 abstract "We performed an analysis of toxicity and survival in stage III melanoma patients receiving adjuvant interferon alfa-2b (IFN). This was a retrospective single-arm analysis of 40 patients with stage III melanoma who received (IFN) administered at maximum tolerated doses of 20 mU/m2/day intravenously (i.v.) for 1 month and 10 mU/m2 three times per week subcutaneously (s.c.) for 48 weeks. Toxicity in our series is comparable to that experienced in the Eastern Cooperative Oncology Group (ECOG) 1684 trial, except for higher rates of dose-limiting myelosuppression and hepatotoxicity. All 40 patients experienced constitutional symptoms, but only 14/40 (35%) experienced grade 3 to 4 symptoms. Of the 40 patients, 36 (90%) experienced neurologic symptoms, but only seven (17.5%) experienced grade 3 to 4 neurotoxicity. Two patients stopped treatment because of severe psychiatric symptoms; one patient attempted suicide, and a psychosis developed in another. Thirty-nine (97.5%) patients experienced myelosuppression; 31 (77.5%) developing grade 3 to 4 myelosuppression. Hepatotoxicity was evident in 39 (97.5%) patients, and 26 (65%) experienced grade 3 to 4 hepatotoxicity. Three patients (7.5%) experienced mild renal toxicity. At a median follow-up of 27 months from initiation of therapy, there have been 19 relapses (47.5% disease-free survival [DFS]) and 10 deaths (75% OS) resulting from progression of disease. The DFS compares with the treatment arm in ECOG 1684 at 27 months, but overall survival is higher in our series of patients at the same time point. In a single program setting, IFN can be administered with similar side effects and outcome profiles seen in multi-institutional studies. Modifications in the induction regimen resulted in notably higher hematologic and hepatic toxicities but did not preclude administering further therapy and did not result in increased attrition rate among patients: only nine patients (22.5%) had their treatment stopped as a result of IFN-related toxicity. In comparison, 26% of patients had to have their treatment discontinued because of toxicity in ECOG 1684." @default.
- W192248603 created "2016-06-24" @default.
- W192248603 creator A5005034815 @default.
- W192248603 creator A5011453882 @default.
- W192248603 creator A5017303827 @default.
- W192248603 creator A5025009665 @default.
- W192248603 creator A5025710827 @default.
- W192248603 creator A5042980318 @default.
- W192248603 creator A5043519976 @default.
- W192248603 creator A5044032877 @default.
- W192248603 creator A5045385836 @default.
- W192248603 creator A5046623395 @default.
- W192248603 creator A5050751226 @default.
- W192248603 creator A5054499110 @default.
- W192248603 creator A5068050082 @default.
- W192248603 creator A5075015860 @default.
- W192248603 creator A5076793020 @default.
- W192248603 creator A5077588536 @default.
- W192248603 creator A5084436319 @default.
- W192248603 creator A5084967339 @default.
- W192248603 date "2000-07-06" @default.
- W192248603 modified "2023-09-27" @default.
- W192248603 title "Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma." @default.
- W192248603 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10882328" @default.
- W192248603 hasPublicationYear "2000" @default.
- W192248603 type Work @default.
- W192248603 sameAs 192248603 @default.
- W192248603 citedByCount "9" @default.
- W192248603 countsByYear W1922486032014 @default.
- W192248603 countsByYear W1922486032015 @default.
- W192248603 crossrefType "journal-article" @default.
- W192248603 hasAuthorship W192248603A5005034815 @default.
- W192248603 hasAuthorship W192248603A5011453882 @default.
- W192248603 hasAuthorship W192248603A5017303827 @default.
- W192248603 hasAuthorship W192248603A5025009665 @default.
- W192248603 hasAuthorship W192248603A5025710827 @default.
- W192248603 hasAuthorship W192248603A5042980318 @default.
- W192248603 hasAuthorship W192248603A5043519976 @default.
- W192248603 hasAuthorship W192248603A5044032877 @default.
- W192248603 hasAuthorship W192248603A5045385836 @default.
- W192248603 hasAuthorship W192248603A5046623395 @default.
- W192248603 hasAuthorship W192248603A5050751226 @default.
- W192248603 hasAuthorship W192248603A5054499110 @default.
- W192248603 hasAuthorship W192248603A5068050082 @default.
- W192248603 hasAuthorship W192248603A5075015860 @default.
- W192248603 hasAuthorship W192248603A5076793020 @default.
- W192248603 hasAuthorship W192248603A5077588536 @default.
- W192248603 hasAuthorship W192248603A5084436319 @default.
- W192248603 hasAuthorship W192248603A5084967339 @default.
- W192248603 hasConcept C126322002 @default.
- W192248603 hasConcept C141071460 @default.
- W192248603 hasConcept C146357865 @default.
- W192248603 hasConcept C151730666 @default.
- W192248603 hasConcept C2777658100 @default.
- W192248603 hasConcept C2777863537 @default.
- W192248603 hasConcept C29730261 @default.
- W192248603 hasConcept C502942594 @default.
- W192248603 hasConcept C71924100 @default.
- W192248603 hasConcept C86803240 @default.
- W192248603 hasConcept C90924648 @default.
- W192248603 hasConceptScore W192248603C126322002 @default.
- W192248603 hasConceptScore W192248603C141071460 @default.
- W192248603 hasConceptScore W192248603C146357865 @default.
- W192248603 hasConceptScore W192248603C151730666 @default.
- W192248603 hasConceptScore W192248603C2777658100 @default.
- W192248603 hasConceptScore W192248603C2777863537 @default.
- W192248603 hasConceptScore W192248603C29730261 @default.
- W192248603 hasConceptScore W192248603C502942594 @default.
- W192248603 hasConceptScore W192248603C71924100 @default.
- W192248603 hasConceptScore W192248603C86803240 @default.
- W192248603 hasConceptScore W192248603C90924648 @default.
- W192248603 hasIssue "3" @default.
- W192248603 hasLocation W1922486031 @default.
- W192248603 hasOpenAccess W192248603 @default.
- W192248603 hasPrimaryLocation W1922486031 @default.
- W192248603 hasRelatedWork W1911828475 @default.
- W192248603 hasRelatedWork W1976786986 @default.
- W192248603 hasRelatedWork W2013259535 @default.
- W192248603 hasRelatedWork W2090324800 @default.
- W192248603 hasRelatedWork W2222337716 @default.
- W192248603 hasRelatedWork W2292630588 @default.
- W192248603 hasRelatedWork W2592672458 @default.
- W192248603 hasRelatedWork W3094262725 @default.
- W192248603 hasRelatedWork W4252206465 @default.
- W192248603 hasRelatedWork W2059275324 @default.
- W192248603 hasVolume "6" @default.
- W192248603 isParatext "false" @default.
- W192248603 isRetracted "false" @default.
- W192248603 magId "192248603" @default.
- W192248603 workType "article" @default.